CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 128 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q2 2023. The put-call ratio across all filers is 1.90 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $79,068 | -26.8% | 3,622 | +6.6% | 0.00% | -20.0% |
| Q2 2023 | $108,022 | +34.4% | 3,398 | +3.1% | 0.01% | +25.0% |
| Q1 2023 | $80,365 | -29.0% | 3,295 | -8.1% | 0.00% | -20.0% |
| Q4 2022 | $113,134 | +19.6% | 3,587 | +7.2% | 0.01% | 0.0% |
| Q3 2022 | $94,586 | +6.9% | 3,347 | 0.0% | 0.01% | +25.0% |
| Q2 2022 | $88,495 | -9.8% | 3,347 | +19.4% | 0.00% | 0.0% |
| Q1 2022 | $98,133 | -75.0% | 2,803 | -76.8% | 0.00% | -20.0% |
| Q4 2021 | $391,893 | +13.2% | 12,088 | +3.0% | 0.01% | 0.0% |
| Q3 2021 | $346,124 | +11.2% | 11,733 | -3.5% | 0.01% | +25.0% |
| Q2 2021 | $311,360 | – | 12,153 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,199,729 | $1,314,160,084 | 42.08% |
| Perceptive Advisors | 10,088,385 | $220,229,445 | 7.35% |
| Finepoint Capital LP | 563,345 | $12,297,821 | 6.12% |
| Affinity Asset Advisors, LLC | 685,061 | $14,954,882 | 4.21% |
| Paradigm Biocapital Advisors LP | 2,532,972 | $55,294,779 | 3.75% |
| Logos Global Management LP | 700,000 | $15,281,000 | 2.04% |
| Artal Group S.A. | 1,638,858 | $35,776 | 1.53% |
| Rock Springs Capital Management LP | 2,529,116 | $55,210,602 | 1.48% |
| GREAT POINT PARTNERS LLC | 215,000 | $4,693,450 | 0.86% |
| Frazier Life Sciences Management, L.P. | 393,000 | $8,579,190 | 0.57% |